Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH

European Journal of Heart Failure

Volumn 17, Issue 12, 2015, Pages 1271-1282

  Meijers, Wouter C ^a   De Boer, Rudolf A ^a   Van Veldhuisen, Dirk J ^a   Jaarsma, Tiny ^b   Hillege, Hans L ^a   Maisel, Alan S ^c   Di Somma, Salvatore ^d   Voors, Adriaan A ^a   Peacock, W Frank ^e  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LINKÖPING UNIVERSITY   (Sweden)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarker; Galectin 3; Heart failure; N terminal pro B type natriuretic peptide; Prognosis; Risk stratification

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; GALECTIN 3; TRANSFORMING GROWTH FACTOR BETA; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1A; UNCLASSIFIED DRUG; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; ARTICLE; FEMALE; HEART FAILURE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; HOSPITALIZATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

AGED; BIOMARKERS; FEMALE; GALECTIN 3; HEART FAILURE; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; NATRIURETIC PEPTIDE, BRAIN; PATIENT READMISSION; PEPTIDE FRAGMENTS;

EID: 84949488194     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.407     Document Type: Article

References (47)

1. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ,. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002; 4: 361-371.
2. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC, OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296: 2217-2226.
3. Jencks SF, Williams MV, Coleman EA,. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009; 360: 1418-1428.
4. Setoguchi S, Stevenson LW, Schneeweiss S,. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007; 154: 260-266.
5. Vazquez R, Bayes-Genis A, Cygankiewicz I, Pascual-Figal D, Grigorian-Shamagian L, Pavon R, Gonzalez-Juanatey JR, Cubero JM, Pastor L, Ordonez-Llanos J, Cinca J, de Luna AB, MUSIC Investigators. The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. Eur Heart J 2009; 30: 1088-1096.
6. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M,. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113: 1424-1433.
7. O'Connor CM, Hasselblad V, Mehta RH, Tasissa G, Califf RM, Fiuzat M, Rogers JG, Leier CV, Stevenson LW,. Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. J Am Coll Cardiol 2010; 55: 872-878.
8. de Boer RA, Daniels LB, Maisel AS, Januzzi JL Jr., State of the art: newer biomarkers in heart failure. Eur J Heart Fail 2015; 17: 559-569.
9. Cheng JM, Akkerhuis KM, Battes LC, van Vark LC, Hillege HL, Paulus WJ, Boersma E, Kardys I,. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail 2013; 15: 1350-1362.
10. Peacock WF,4th, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH, ADHERE Investigators. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008; 358: 2117-2126.
11. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M, ADHERE Scientific Advisory Committee and Investigators. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007; 49: 1943-1950.
12. Fonarow GC, Adams KF,Jr, Abraham WT, Yancy CW, Boscardin WJ, ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005; 293: 572-580.
13. Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ, Sanderman R, Hoes AW, van Gilst WH, Lok DJ, Dunselman PH, Tijssen JG, Hillege HL, van Veldhuisen DJ, Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) Investigators. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med 2008; 168: 316-324.
14. Jaarsma T, Van Der Wal MH, Hogenhuis J, Lesman I, Luttik ML, Veeger NJ, Van Veldhuisen DJ,. Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure. Eur J Heart Fail 2004; 6: 227-233.
15. van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HL,. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013; 61: 1498-1506.
16. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ,. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43: 60-68.
17. Meijers WC, Januzzi JL, deFilippi C, Adourian AS, Shah SJ, van Veldhuisen DJ, de Boer RA,. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of three clinical trials. Am Heart J 2014; 167: 853-860.
18. Christenson RH, Duh SH, Wu AH, Smith A, Abel G, deFilippi CR, Wang S, Adourian A, Adiletto C, Gardiner P,. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. Clin Biochem 2010; 43: 683-690.
19. Meijers WC, van der Velde AR, de Boer RA,. The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure. Expert Rev Mol Diagn 2014; 14: 257-266.
20. Rahimi K, Bennett D, Conrad N, Williams TM, Basu J, Dwight J, Woodward M, Patel A, McMurray J, MacMahon S,. Risk prediction in patients with heart failure: a systematic review and analysis. JACC Heart Fail 2014; 5: 440-446.
21. Ouwerkerk W, Voors AA, Zwinderman AH,. Factors influencing the predictive power of models for predicting mortality and/or heart-failure hospitalization in patients with heart failure. JACC Heart Fail 2014; 5: 429-436.
22. Postmus D, van Veldhuisen DJ, Jaarsma T, Luttik ML, Lassus J, Mebazaa A, Nieminen MS, Harjola VP, Lewsey J, Buskens E, Hillege HL,. The COACH risk engine: a multistate model for predicting survival and hospitalization in patients with heart failure. Eur J Heart Fail 2012; 14: 168-175.
23. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845.
24. Pencina MJ, D'Agostino RB S, Steyerberg EW,. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11-21.
25. Marti CN, Khan H, Mann DL, Georgiopoulou VV, Bibbins-Domingo K, Harris T, Koster A, Newman A, Kritchevsky SB, Kalogeropoulos AP, Butler J, Health ABC Study. Soluble tumor necrosis factor receptors and heart failure risk in older adults: Health, Aging, and Body Composition (Health ABC) Study. Circ Heart Fail 2014; 7: 5-11.
26. Behnes M, Hoffmann U, Lang S, Weiss C, Ahmad-Nejad P, Neumaier M, Borggrefe M, Brueckmann M,. Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure. Clin Res Cardiol 2011; 100: 335-342.
27. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, Andre S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM,. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110: 3121-3128.
28. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM,. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48: 1217-1224.
29. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ,. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009; 11: 811-817.
30. Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, van der Harst P, Pitt B, Goldstein IJ, Koerts JA, van Veldhuisen DJ, Bank RA, van Gilst WH, Sillje HH, de Boer RA,. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013; 6: 107-117.
31. Chen A, Hou W, Zhang Y, Chen Y, He B,. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. Int J Cardiol 2015; 182: 168-170.
32. de Boer RA, Edelmann F, Cohen-Solal A, Mamas MA, Maisel A, Pieske B,. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 2013; 15: 1095-1101.
33. Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, Duvinage A, Unkelbach I, Dungen HD, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Stough WG, Pieske BM,. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail 2015; 17: 214-223.
34. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL,. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 16: e147-e239.
35. De Boer RA, Pinto YM, Van Veldhuisen DJ,. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 2003; 10: 113-126.
36. Ruifrok WP, Qian C, Sillje HH, van Goor H, van Veldhuisen DJ, van Gilst WH, de Boer RA,. Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin. J Mol Med (Berl) 2011; 89: 377-387.
37. Salah K, Kok WE, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Bayes-Genis A, Verdiani V, Bettari L, Lazzarini V, Damman P, Tijssen JG, Pinto YM,. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score. Heart 2014; 100: 115-125.
38. O'Brien RJ, Squire IB, Demme B, Davies JE, Ng LL,. Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail 2003; 5: 499-506.
39. Troughton R, Michael Felker G, Januzzi JL Jr., Natriuretic peptide-guided heart failure management. Eur Heart J 2014; 35: 16-24.
40. Maisel A, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng LL, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Hartmann O, Morgenthaler NG, Anker SD,. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2011; 58: 1057-1067.
41. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ, de Boer RA,. prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 2013; 6: 219-226.
42. Lok DJ, Lok SI, Bruggink-Andre de la Porte PW, Badings E, Lipsic E, van Wijngaarden J, de Boer RA, van Veldhuisen DJ, van der Meer P,. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 2013; 102: 103-110.
43. Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN,. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013; 15: 511-518.
44. Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P, Gaggin HK, Bhardwaj A, Januzzi JL,. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail 2013; 15: 1157-1163.
45. Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, Cohn JN, Val-HeFT Investigators,. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008; 52: 997-1003.
46. Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR,. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA 2004; 291: 1358-1367.
47. Grafft CA, McDonald FS, Ruud KL, Liesinger JT, Johnson MG, Naessens JM,. Effect of hospital follow-up appointment on clinical event outcomes and mortality. Arch Intern Med 2010; 170: 955-960.